2025
Evaluating the association between routine pneumococcal vaccination and COVID-19 severity among older adults in the United States: A case control study
Prunas O, Tiu A, Shioda K, Bansal S, Weinberger D. Evaluating the association between routine pneumococcal vaccination and COVID-19 severity among older adults in the United States: A case control study. Vaccine X 2025, 24: 100622. DOI: 10.1016/j.jvacx.2025.100622.Peer-Reviewed Original ResearchCOVID-19 patientsCase-control studyIntensive care unitSevere respiratory symptomsPneumococcal vaccineSevere outcomesRespiratory symptomsOdds of progressionReceipt of pneumococcal vaccinationCOVID-19 severitySevere COVID-19 outcomesLogistic regression modelsSevere acute respiratory syndrome coronavirus 2Streptococcus pneumoniaeAcute respiratory syndrome coronavirus 2Non-severeRespiratory syndrome coronavirus 2Care unitControlled studiesPatientsSyndrome coronavirus 2COVID-19 outcomesSARS-CoV-2VaccineCoronavirus 2Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severity
2022
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. JAMA Internal Medicine 2022, 182: 179-184. PMID: 34846533, PMCID: PMC8634151, DOI: 10.1001/jamainternmed.2021.7382.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Maccabi Healthcare ServicesBooster doseBNT162b2 vaccineMRNA vaccinesPositive SARS-CoV-2 polymerase chain reaction testSARS-CoV-2 polymerase chain reaction testPreliminary retrospective case–control studyRetrospective case-control studyPositive PCR test resultsBNT162b2 mRNA vaccineVaccine-derived protectionTest-negative designDuration of immunityCase-control studyPolymerase chain reaction testEstimated odds ratioHealthcare servicesCase-control analysisPCR test resultsPositive test resultsChain reaction testCase-control designTesting PositiveOdds ratio
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply